All programs are available on VHS videotapes as well as DVDs ($35 charge for conversion to other formats).
For orders over 20 items, please contact us directly to obtain shipping rates.
Medical Science Horizons: Recombinant Technology
Savio L. C. Woo, PhD; Alan Bernstein, PhD; Nelson A. Wivel, MD
Gene Therapy in the 21st century; Ethical considerations of the replication of genes in therapy; Diseases currently in treatment.
Pharmacology of Neuropathic Pain: Corticosteroids, Anesthetics, Anticonvulsants
Mark Boswell, MD
(No Description Available.)
AIDS Research Forum: Advances In Use of
Non-nucleoside Reverse Transcriptase Inhibitors
John G. Bartlett, MD; John P. Phair, MD
Provide a background for understanding the pharmacology efficacy and potential utility of a new class of antiretroviral agents, the non-nucleoside reverse transcriptase inhibitors.
Role in the Management ofHIV Disease
Dale Kummerle, PharmD; Victoria Earlywine, PharmD; Stephen Piscitelli, PharmD
Compliance with HIV Medications; Drug Interaction with HIV Medications; Practical Considerations: Circumventing Side Effects
Issues in Aminoglycoside Therapy
Vanessa L. Kluth, PharmD; Melissa Cordell, RN; Ed Septimus, MD
Identify important factors when choosing the appropriate antimicrobial agent for a given infection; Describe the mechanism of action and spectrum of active aminoglycosides; Discuss rationale for once-daily dosing; State appropriate timing of drug sampling as it relates to aminoglycoside dosing; Understand the importance of the interpretation of results.
Advances in the Management of the Side Effects of Chemotherapy
Stephen L. Huber, MS, RPh; Cynthia Radford; Steven M. Grunberg, MD
This program features leading healthcare professionals giving presentations on the latest advances in the management of the side effects of chemotherapy. Discussions will include information on pharmacoeconomics of antiemetic therapy in oncology and appropriate use of antiemetic therapy. Specific topics include: Enhancing the Value of Antiemetics in Oncology; Reimbursement Environment in Antiemetic Therapy; Challenges in Antiemetic Therapy.
The Dose Response Relationship of 5HT3 Antiemetics
Celeste Lindley, PharmD; Steven M. Grundberg, MD; John D. Hainsworth, MD; Stephen L. Huber, MS, RPh
Learn about determining the emetogenic potential for chemotherapy agents; review new class system and algorithm for determining emetogenic potential of combo chemotherapy regimens. Discussions include the rationale for stratification of antiemetic dosage based on the emetogenicicity of the chemotherapy regimen; appreciating the cost and revenue comparisons for the 5HT3 antiemetics based on dosing considerations and identifing strategies for enhancing the antiemetics in a variety of practice settings.
New Therapeutic Advances in the Medical Treatment of Glaucoma
Richard G. Fiscella, RPh, MPH; Richard A. Quinones, MD; Bruce I. Gaynes, OD, MS, PharmD
Define glaucoma and explain disease manifestation; List different treatment options available; Describe the traditional medical treatments available; Understand the new medical agents available and how they may change therapeutic options for the treatment of glaucoma.
Advances in Managing Alzheimer's Disease
Kevin M. Furmaga, PharmD; Michael Koronkowski, PharmD; Vinod Kumar, MD, MRC
Topics include: Pathophysiology and Non-Cognitive Symptoms of Alzheimer's Disease; Cognitive Symptoms of Alzheimer's Disease; Future Directions in Drug Therapy for Alzheimer's Disease.
Management of the Side Effects of Chemotherapy
Steven M. Grunberg, MD; John D. Hainsworth, MD; Paul J. Hesketh, MD; Jane Nolte, PharmD
Pharmacoeconomics of antiemetic therapy, oral antiemetics replacing IV antiemetics, appropriate use of antiemetic therapy, and the management of cisplatin-induced delayed emesis.
Rationale for Achieving Optimal Glycemic Control in Diabetic Patients
R. Keith Campbell, RPh, FASHP, CDE; Julie C. Oki, PharmD, BCPS
Provide an update on the treatment of diabetes, including a review of the rationale for and means of achieving optimal glycemic control. Specific topics covered include: Discussion of the rationale for achieving optimal glycemic control in both type I and type II diabetic patients; Recent advances which may aid in achieving optimal glycemic control in type II diabetic patients; Methods to improve glycemic control in patients with type I diabetes.
Therapeutic Management of Congestive Heart Failure
J. Herbert Patterson, PharmD; Michael B. Bottorff, PharmD; Barry Bleske, PharmD
Pathophysiology of heart failure and it's role in contributing to the morbiity and mortality of heart failure; be able to identify the most appropriate therapy for a patient to optimize outcomes; when a specific therapy is contraindicated, be able to identify alternate appropriate therapies to optimize therapeutic outcomes. Be able to list potential drug therapies that may be useful for heart failure.
Improving Cardiovascular Risk
Robert B. Supernaw, PharmD; Mary J. Ferrill, PharmD; Sian Carr-Lopez, PharmD
Hyperlipidemia: Reducing Risk by Reducing Cholesterol; Should We Be Treating Patients With Medication?; Hypertension and Cardiovascular Risk: Will Controlling Blood Pressure Reduce the Risk?
Advances in Pharmaceutical Care for Patients with Asthma
Program provides participants w/ an update on new guidelines for the management of asthma, roles that pharmacists can play in the treatment of patients w/ asthma, and the role that medications affecting leukotriene synthesis or action may play in therapy.
Health Outcomes Research
Barry Kass, RPh, MBA; Judith Barr, ScD; Gerald E. Schumacher, PharmD, PhD
This program provides an introduction to health outcomes research with an examination of the links among structure, process, and outcomes in clinical interventions and health delivery systems. System-based and patient-centered outcomes will be discussed with administrative, clinical and economic examples drawn from therapeutic drug monitoring, DUR/DUE, and other pharmacy-related topics.
Formulary Development and Compliance
Perry Cohen; Joseph Ober, Pharm.D; Sharon Montgomery, MA, RPh; J. Russell May, PharmD
Explains the evolution of managed care, discusses the important issues facing managed care including outcomes, disease management, and pharmacoeconomics; formulary development; explains the impact of the formulary on the pharmacist, hospital and community.
Pharmaceutical Care: Quality of Life
Walter J. Curran, Jr., MD; David S. Ettinger, MD; Chandra P. Belani, MD; Dawn Moose, MD
Integration of Chemotherapy and Radiation for Non-Small Cell Lung Cancer; New Drugs in Treatment of NSCLC; Recent Improvements in the Management of NSCLC; Management of Anorexia and Cachexia for Patients w/ NSCLC
Evaluation and Utilization of Pharmacoeconomic Research
Thomas O'Conner, PharmD, MBA; Michael A. Mancano, PharmD; Barbara Goppold, RPh
Identify the four basic types of pharmacoeconomic analyses; Discuss and categorize the types of relevant costs; Evaluate the criteria for a well designed pharmacoeconomic study; Interpret study results; Suggest the most appropriate treatment modality based upon study results; Identify the potential value and uses of pharmacoeconomic research in the managed care environment.
Psychiatry Update: Panic Disorder
S.A. Saeed, MD; William C. Sanderson, PhD
Treatment of Panic Disorder and Diagnosis of Panic Disorder.
The Pharmacist’s Role in Optimizing Patient Compliance
Thomas O'Conner, PharmD, MBA; Elaine D. Mackowiak, PhD; Robert S. Thompson, PhD
Patient Non-Compliance, A Major Obstacle to Improving Health Care Outcomes; Counseling and Reinforcing Proper Self-Medication; Compliance Devices.
Role of the Pharmacist in Compliance Enhancement
Mickey Smith, RPh, PhD; Jack Fincham, RPh, PhD; J. Lyle Bootman, RPh, PhD; Kent Summers, RPh, PhD; Albert I. Wertheimer, RPh, PhD
Describes the methods of detecting and predicting non-compliance, identifies the economic consequences of non-compliance to healthcare generally and in pharmacy practice, and discusses how to choose interventions best suited to enhance compliance.
Advances in Managing & Treating Attention Deficit Disorder
Joseph P. Horrigan, MD; L. Jarrett Barnhill, Jr., MD; William Lord Coleman, MD
Attention Deficit Hyperactivity Disorder Throughout the Life Cycle; Psychiatric Comorbidity; The Impact of Attention Deficit on Learning.
Current Concepts in Hypertension Management
(No Description Available.)
Managing Hyperlipidemia to Meet Patient Care Needs
Bogomir M. Kuhar, PharmD; Jean-Venable "Kelly" R. Goode, PharmD, BCPS; Kim Malone, BS
Describe current rationale and epidemiology of cholesterol management. Review cardiovascular risk factors and current NCEP guidelines for treatment. List treatment approaches to achieving NCEP goals. List drug strategies and the major adverse reactions in treating hyperlipidemia. List the benefits of a pharmacy-based lipid screening and monitoring program. Explain procedures necessary for making a hyperlipidemia clinic. Identify the strategies needed to implement & keep a pharmacy-based clinic. Develop a marketing plan for a pharmacy-based clinic.
Using Claims Data in HMO to Assess Medication Usage Emphasizing Appropriate Prescribing
Edward P. Armstrong, PharmD; Frederick Pfeiffer, RPh, MS, PharmD; Tim Sawyers, RPh, MBA, CDE;
Provide information for using claims data to assess drug therapy; Analyze claims data to determine non-adherence to chronic medications; Understand how to access medical and pharmacy claims; Differentiate medical from pharmacy claims data and report generation; Identify specific depressions management problems in a managed care setting.
Therapeutic Noncompliance in Medication Usage
Frederick Pfeiffer, PharmD; Richard Herrier, PharmD, CPE
Assess the impact of medication nonadherance to the overall cost of healthcare in the US; Determine the need for patient education regarding medications for hypertension as it relates to drug defaulting; Determine the role of common annoying side effects with diuretics in the perpetuation of therapeutic nonadherance; Describe three misconceptions regarding compliance issues; List three main factors that are required for optimal patient compliance.
Art Matthys, RPh; William Letender, MS, RPh; Dave Mason, RPh; Loyd Allen, PhD
Define the terms pharmacy, manufacturing, compounding, and triad; Identify areas where pharmacists can solve non-compliance problems using compounding services; List the unique dosage forms that are available to healthcare professionals. Understand how pharmacists meet the unique needs of patients at their practice sites; List the factors that exempt pharmacists from the Federal Food and Drug and Cosmetic Act; Realize the value of compounding services in terms of patient compliance and patient needs. Identify areas of practice could potentially benefit compounding; Select a course of action to take when filling a compounded prescription .
Advances in Treating Social Phobia
Atezaz Saeed, MD; Timothy Bruce, PhD
Recognize and formally diagnose social phobia using DSM-IV; Differentiate social phobia from other primary and secondary anxiety disorders; Identify the disorders which tend to be commonly comorbid with social phobia; understand indications for drug therapy, cognitive behavior therapy, and combined treatment for social phobia; Describe classes of drugs most appropriate in treatment and first line treatments and follow-up treatment in case of non-response.
A Closer Look at the Diagnosis & Treatment of Schizophrenia
Mark D. Watanabe, PharmD, PhD; S. Charles Schulz, MD; Peter F. Buckley, MD
Define the demographic characteristics of schizophrenia; Appreciate the core diagnostic features of schizophrenia; Discuss which conditions mimic the presentation of schizophrenia; Understand the role of ancillary tests and other information in differentiating schizophrenia from neurological conditions; Identify new drugs available for full syndrome of schizophrenia; Distinguish the difference between the effects of traditional drugs and new drugs; Describe the current theories proposed for the pathogenesis of schizophrenia and their implications for rational drug therapy.
NAFTA & the U.S. Pharmacist
Barry Coleman, RPh (Moderator); T. L. Vordenbaumen, Sr., RPh; Orville A. Wagner; Dr. Jaime Kravzov
A prominent international faculty that will "explore the pharmacy implications of NAFTA with an emphasis on education and practice needs, as well as quality and pricing in drug manufacturing".
Compensation for Professional Services in Delivery of Pharmaceutical Care
Michael T. Rupp, PhD, RPh
Discussion on the status of recent initiatives to create a national standard for the routine documentation and transmission of clinical and billing information related to the delivery of pharmaceutical care between pharmacy providers and third-parties.
Pharmacy Update: Advances in Determining & Treating Schizophrenia
Mark Watanabe, PharmD; Barbara Poddig, PharmD, BCPP; LaGenia Bailey, PharmD; Mark E. Schneiderhan, PharmD, BCPP
Describe the therapeutic goals of using typical antipsychotic agents; Understand the common side effects of typical antipsychotic agents; Identify characteristics of "High potency" vs "Low potency" antipsychotic agents.